These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 30166303)

  • 1. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
    Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
    BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
    Foley P; Parker RA; de Angelis F; Connick P; Chandran S; Young C; Weir CJ; Chataway J;
    Mult Scler Relat Disord; 2022 Jul; 63():103925. PubMed ID: 35671671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
    John NA; Solanky BS; De Angelis F; Parker RA; Weir CJ; Stutters J; Carrasco FP; Schneider T; Doshi A; Calvi A; Williams T; Plantone D; Monteverdi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
    Wong C; Dakin RS; Williamson J; Newton J; Steven M; Colville S; Stavrou M; Gregory JM; Elliott E; Mehta AR; Chataway J; Swingler RJ; Parker RA; Weir CJ; Stallard N; Parmar MKB; Macleod MR; Pal S; Chandran S
    BMJ Open; 2022 Jul; 12(7):e064173. PubMed ID: 35798516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
    Blackstone J; Williams T; Nicholas JM; Bordea E; De Angelis F; Bianchi A; Calvi A; Doshi A; John N; Apap Mangion S; Wade C; Merry R; Barton G; Lyle D; Jarman E; Mahad D; Shehu A; Arun T; McDonnell G; Geraldes R; Craner M; Hillier C; Ganesalingam J; Fisniku L; Hobart J; Spilker C; Robertson N; Kalra S; Pluchino S; Harikrishnan S; Mattoscio M; Harrower T; Young C; Lee M; Chhetri S; Ahmed F; Rog D; Silber E; Gallagher P; Duddy M; Straukiene A; Nicholas R; Rice C; Nixon SJ; Beveridge J; Hawton A; Tebbs S; Braisher M; Giovannoni G; Ciccarelli O; Greenwood J; Thompson AJ; Hunter R; Pavitt S; Pearson O; Evangelou N; Sharrack B; Galea I; Chandran S; Ford HL; Frost C; Chataway J
    BMJ Open; 2024 Sep; 14(9):e086414. PubMed ID: 39284697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
    Solanky BS; John NA; DeAngelis F; Stutters J; Prados F; Schneider T; Parker RA; Weir CJ; Monteverdi A; Plantone D; Doshi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
    Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
    Trials; 2014 Jan; 15():37. PubMed ID: 24460863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
    McKee JB; Elston J; Evangelou N; Gerry S; Fugger L; Kennard C; Kong Y; Palace J; Craner M
    BMJ Open; 2015 Nov; 5(11):e009200. PubMed ID: 26553836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
    Arun T; Tomassini V; Sbardella E; de Ruiter MB; Matthews L; Leite MI; Gelineau-Morel R; Cavey A; Vergo S; Craner M; Fugger L; Rovira A; Jenkinson M; Palace J
    Brain; 2013 Jan; 136(Pt 1):106-15. PubMed ID: 23365093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Cambron M; Mostert J; D'Hooghe M; Nagels G; Willekens B; Debruyne J; Algoed L; Verhagen W; Hupperts R; Heersema D; De Keyser J;
    Mult Scler; 2019 Nov; 25(13):1728-1735. PubMed ID: 31218911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
    Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
    Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
    De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
    Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.